Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up

Carlo Gambacorti-Passerini, Tim H. Brümmendorf, Dong Wook Kim, Anna G. Turkina, Tamas Masszi, Sarit Assouline, Simon Durrant, Hagop M. Kantarjian, H. Jean Khoury, Andrey Zaritskey, Zhi Xiang Shen, Jie Jin, Edo Vellenga, Ricardo Pasquini, Vikram Mathews, Francisco Cervantes, Nadine Besson, Kathleen Turnbull, Eric Leip, Virginia KellyJorge E. Cortes

Research output: Contribution to journal › Article › peer-review

95 Scopus citations

Fingerprint

Dive into the research topics of 'Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up'. Together they form a unique fingerprint.

Medicine & Life Sciences